Navigation Links
Tadalafil shows promise for relief of lower urinary tract symptoms associated with BPH
Date:8/18/2008

New York, August 19, 2008 Men with signs of benign prostatic hyperplasia (BPH) can be helped with a daily dose of erectile dysfunction drug tadalafil (Cialis) to relieve associated lower urinary tract symptoms (LUTS), according to a new study published in the October 2008 issue of The Journal of Urology. Researchers from the University of Texas Southwestern Medical Center at Dallas, Northwestern University and Lilly Research Laboratories report on a randomized, double-blind, placebo-controlled study of over 1000 men in ten countries.

Claus G. Roehrborn, MD, Professor of Urology, University of Texas Southwestern Medical Center, states, "Since reports of erectile dysfunction (ED) incidence, pathophysiology and treatment have shown a possible link between BPH LUTS and ED. PDE5 inhibitors like tadalafil (Cialis) have received increased attention for treating BPH LUTS, although they are currently only approved for ED. The half-life of tadalafil is 17.5 hours, making it suitable as once daily therapy. Although the precise mechanism of action by which PDE5 inhibitors may alleviate LUTS is not completely understood, several putative mechanisms are currently under investigation."

Men with signs of BPH may experience LUTS, such as urinary frequency, urgency, intermittence, nocturia, straining, incomplete emptying or a weak urinary stream. LUTS increase with age with an overall prevalence of greater than 50% in men 50 years or older. Drugs currently used to treat these symptoms can produce unwanted side effects, including dizziness, low blood pressure and sexual dysfunction.

Participants in the tadalafil study were required to have at least a 6-month history of LUTS secondary to BPH. Subjects with a high PSA (more than 10 ng/ml) were excluded, as were subjects with other complicating conditions or conflicting drug treatments. Anyone who had undergone treatment for erectile dysfunction or other BPH treatments underwent a 4-week treatment-free screening period. All participants then received placebo for 4 weeks prior to randomization. The 1056 subjects were then divided randomly into 5 groups that received a placebo, or doses of 2.5, 5.0, 10.0 or 20.0 mg/day of tadalafil.

Using the International Prostate Symptom Score (I-PSS), a validated seven-item questionnaire about LUTS occurring within the last month, the researchers found that all doses of tadalafil were superior to placebo for relieving LUTS, with statistically significant effects at 4, 8 and 12 weeks. The treatments decreased I-PSS scores from 3.9 to 5.2 points in the different dosage groups, a clinically meaningful improvement according to the guidelines of the American Urological Association. Of the doses studied, 5 mg per day improved the I-PSS by 4.9 points and provided the best risk-benefit profile.


'/>"/>

Contact: Linda Gruner
l.gruner@elsevier.com
212-633-3923
Elsevier Health Sciences
Source:Eurekalert

Related medicine news :

1. FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. New research shows how chronic stress worsens neurodegenerative disease course
4. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows
5. Circulating fats kill transplanted pancreas cells, study shows
6. New Heart Pump Shows Promise in Trial
7. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
8. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
9. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
10. Amid Improving Life Expectancy Rates, Risk of Premature Death is Still Significant for Americans, New Study Shows
11. Avocados may help prevent oral cancer, OSU study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... Alert Sentry Group LLC., a leader in the Personal Emergency ... iSAFE and the iSAFE Plus. These iSAFE products are the most affordable and most ... and iSAFE Plus offer direct GPS Location and two-way calling with the push of ...
(Date:3/28/2017)... ... ... WHO: , Dr. Paul Thomas; Dr. Brian Hooker; Dr. Judy Mikovits; Dr. ... will speak to the press on behalf of over 200 doctors, scientists, and scientific ... commission. , WHERE: , Zenger Room, National Press Club, 529 14th Street NW, ...
(Date:3/28/2017)... VA (PRWEB) , ... March 28, 2017 , ... The ... Still, MHA, FRBMA, has begun to serve as its new executive director. Mr. Still ... the Executive Search Committee. , “Bob, as he is known to our members, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning ... will begin serving as new board chair for Orange County health care system ... the remainder of soon-to-be former chair Mark Refowitz’s term, which runs through June ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... of two biometric time and attendance tracking products: the new NCheck Cloud Bio ... Cloud Bio Attendance uses biometric face recognition to enable users to check in ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... SAN MATEO, Calif. , March 27, 2017 ... has been acquired by Ethicon, a division of ... Reflux Management System for the treatment of gastro-esophageal ... on magnetic sphincter augmentation (MSA) technology and the ... European medical centers. Torax Medical was ...
(Date:3/27/2017)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... AGI-134, an immunotherapy for the treatment of multiple cancers, obtained ... featured at the upcoming American Association for Cancer Research ... to be held on April 1-5, 2017. ... An abstract titled ...
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017 ...  is expected to reach USD 16.0 billion by 2025, ... Inc. The growing prevalence of chronic diseases is anticipated ... clinical chemistry analyzers, which thereby widens the scope for ... of geriatric and bariatric population, which is highly susceptible ...
Breaking Medicine Technology: